FeesSafety
Pluang+

CytomX hits $5M milestone with Regeneron on cancer drug collaboration using conditionally activated bispecifics

Company Fundamentals
17 Nov 2026, 23:15 WIB
GlobeNewsWire
View Source
Bullish
CytomX hits $5M milestone with Regeneron on cancer drug collaboration using conditionally activated bispecifics

CytomX Therapeutics announced it reached a $5 million preclinical milestone in its collaboration with Regeneron to develop conditionally activated bispecific antibodies for cancer treatment. This partnership combines CytomX's PROBODY® technology with Regeneron's Veloci-Bi® platform to create therapies that activate only in the tumor environment, potentially reducing side effects. The collaboration, expanded in June 2026, could yield up to $4 billion in milestones and royalties for CytomX. This milestone marks progress toward clinical development of safer, targeted cancer therapies.

Regeneron Pharmaceuticals Inc holds a market cap of $98.52 billion and a dividend yield of 0.39% as of Nov 18, 2026 04:21 WIB on Pluang. The stock is trading at USD 960.52 with a 1-day gain of 0.85%, reflecting steady investor interest. Pluang data shows a full buy order activity with a typical hold time of 109 days, indicating confidence in Regeneron's long-term prospects amid its ongoing collaborations.

More News (REGN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App